Ouerfelli Ouathek, Warren J David, Wilson Rebecca M, Danishefsky Samuel J
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Expert Rev Vaccines. 2005 Oct;4(5):677-85. doi: 10.1586/14760584.4.5.677.
The development of a clinically effective, carbohydrate-based antitumor vaccine is a longstanding ambition in the prevention and treatment of cancer. This review seeks to provide a discussion of some of the unique challenges facing this particular field of immunology. The authors present a historic account of their ongoing research program devoted to the development of fully synthetic, carbohydrate-based anticancer vaccines of clinical value. As will be seen, remarkable advances in carbohydrate and glycopeptide assembly techniques have allowed for the preparation of synthetic constructs of progressively increasing structural complexity. The authors describe the evolution of their synthetic carbohydrate program from first-generation constructs, which were monovalent in nature, to highly complex unimolecular multivalent vaccines, in which multiple carbohydrate antigens are displayed in the context of a single polypeptide backbone. It is the hope that each generation of vaccines represents a move closer to achieving the ultimate objective of developing broadly useful, robust anticancer vaccines.
开发一种临床有效的、基于碳水化合物的抗肿瘤疫苗一直是癌症预防和治疗领域长期以来的目标。本综述旨在探讨这一特殊免疫学领域所面临的一些独特挑战。作者介绍了他们正在进行的研究项目的历史，该项目致力于开发具有临床价值的全合成、基于碳水化合物的抗癌疫苗。可以看出，碳水化合物和糖肽组装技术的显著进展使得能够制备结构复杂性逐渐增加的合成构建体。作者描述了他们的合成碳水化合物项目从本质上为单价的第一代构建体，发展到高度复杂的单分子多价疫苗的过程，在这种疫苗中，多个碳水化合物抗原展示在单个多肽主链的背景下。希望每一代疫苗都代表着朝着开发广泛有用、强大的抗癌疫苗这一最终目标迈进了一步。
